Notably, Holothurin A inhibits prostate cancer growth by reducing PSA expression [163] and modulating androgen receptor (AR) activity through strong binding to the BF3 pocket, as demonstrated by in vitro, in silico, and molecular dynamics studies, suggesting its potential as a treatment for castration-resistant tumors. This evidence concerns the gene AR and prostate carcinoma.